由KMT2A重组的白血病:从机制到药物开发
Patricia Ernst1, Perpetual S Kyei1, Akihiko Yokoyama2
1Department of Pediatrics and of Pharmacology and Cancer Biology Program, University of Colorado, Aurora, Colorado.
Experimental hematology
|September 8, 2025
概括
混合血统白血病 (MLL) 基因中的基因重组会产生驱动白血病的融合coproteins. 针对MLL-MENIN与新抑制剂的相互作用,为这些预后不佳的癌症提供了一个有希望的治疗策略.
科学领域:
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症遗传学 癌症遗传学
背景情况:
- 人类混合血统白血病 (MLL) 基因 (KMT2A) 的基因重组产生与预后不佳白血病相关的融合coproteins.
- 在胚胎发育过程中,MLL作为一个表观遗传调节器,对维持本源性 (HOX) 基因表达至关重要.
- 异常的MLL活动,通常是由于基因重组,导致HOX基因过度表达和白血病转化.
研究的目的:
- 审查野生型MLL功能及其致癌变体的分子机制.
- 详细说明染色体转位如何产生构成性活跃的MLL融合基蛋白.
- 讨论针对MLL融合蛋白的治疗策略,包括MENIN抑制剂.
主要方法:
- 审查目前对MLL基因功能和重组的理解.
- 根据染色体转位,将MLL融合基蛋白分为五大类.
- 对MLL复杂相互作用与基因素乙烯转移酶 (HAT) 和MENIN的分析.
主要成果:
- 在MLL融合瘤蛋白中,白血病转化取决于与MENIN的相互作用.
- 在基因激活过程中,MLL复合体与HATs (MOZ/MORF,HBO1,EP300/CREBBP) 相互作用.
- 异常招募HAT区分MLL融合蛋白与野生型MLL.
结论:
- 对MLL融合coproteins的机械洞察力导致了MENIN抑制剂的开发.
- 针对MLL-MENIN相互作用的MENIN抑制剂正在进入临床实践.
- 预测和治疗对MLL向治疗的耐药性机制至关重要.
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.9K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:10Drugs that Destabilize Microtubules
3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K